{"entity":{"id":"nct05929235","kind":"trial","name":"A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma","aka":[],"tldr":"A phase 1 trial of FX-909 run by Flare Therapeutics Inc., active, not recruiting.","summary":"A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma is a phase 1 interventional study registered as NCT05929235 by Flare Therapeutics Inc., with 120 participants planned, started 2023-08-24, primary completion expected 2027-10-30. Conditions recorded: Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label. Interventions recorded: FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab).","status":"active","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05929235","url":"https://clinicaltrials.gov/study/NCT05929235"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["fx-909"],"companies":["flare-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05929235","phase":"1","setting":"A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 (as Monotherapy or in Combination With Pembrolizumab) in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma","sponsor":"Flare Therapeutics Inc.","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05929235/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"fx-909","kind":"drug","name":"FX-909","route":"/drugs/fx-909/"}],"company":[{"id":"flare-therapeutics","kind":"company","name":"Flare Therapeutics","route":"/companies/flare-therapeutics/"}]}}